Table 1 The important data of four prostate DLBCL patients.
Cases | Age | Admission symptom | TPSA (ng/ml) | Prostate volume (cm3) | Lugano stage | SEER stageb | Surgical method | Pathological diagnosis | Source | Treatment | Response | Lymphoma-specific survival (months)e | Overall survival (months)f | Current status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 67 | Painless total hematuria | 0.073 | 32.36 | IVE | Distant | Biopsy | DLBCL | Not typed | Patient refused further treatment | None | 9.2 | 9.2 | Deceased, other |
2 | 80 | LUTS, abdominal distension | 1.766 | None | IIBE | Regional | Biopsy | DLBCL | GCB | R-CHOP | PR | 47.6 | 47.6 | Deceased, other |
3 | 82 | Elevated PSA, LUTS | 8.476 | 125.28 | IAE | Localized | TURP | DLBCL | GCB | R-CHOP | CR | 6.7 | 62.6 | Alive |
4 | 59 | LUTS, fever, muscle soreness | 1.432 | 71.24 | IIBE | Regional | Biopsy | DLBCL | Non-GCB | 1–3 cycles: R-CHOP; 4–6 cycles: Z-R-CHOP; 7–8 cycles: ZR | CR | 8.3 | 47.2 | Alive |
